Table 1.
Baseline characteristics by study group (mean ± sem).
| Placebo (n = 38) | Simvastatin (n = 39) | P-value (n = 77) | |
|---|---|---|---|
| Age (years)(1) | 64 (53–72) | 63 (53–72) | .70 |
| Years postmenopausal(1) | 18 (6–44) | 19 (7–31) | .80 |
| Scale body weight (kg) | 69.6 ± 1.4 | 64.6 ± 1.8 | .04 |
| Body mass index (kg/m2) | 26.4 ± 0.5 | 24.7 ± 0.7 | .04 |
|
| |||
| Biochemestry | |||
| Plasma | |||
| Calcium (adj.) (mmol/L) | 2.44 ± 0.01 | 2.46 ± 0.01 | .17 |
| Creatinine (mol/L) | 77 ± 2 | 78 ± 2 | .82 |
| Total cholesterol (mmol/L) | 6.4 ± 0.1 | 6.5 ± 0.2 | .69 |
| HDL cholesterol (mmol/L) | 1.8 ± 0.1 | 2.0 ± 0.1 | .14 |
| LDL cholesterol (mmol/L) | 4.0 ± 0.1 | 4.0 ± 0.2 | .99 |
| Triglycerides (mmol/L) | 1.3 ± 0.1 | 1.1 ± 0.1 | .08 |
| P-PTH (pmol/L) | 4.2 ± 0.2 | 4.4 ± 0.2 | .39 |
| 25OHD (nmol/L) | 70 ± 4 | 71 ± 4 | .89 |
| 25OHD <25 nmol/L, N (%) | 2 (5%) | 1 (3%) | .54 |
| 25OHD <50 nmol/L, N (%) | 7 (18%) | 4 (10%) | .35 |
| 25OHD <80 nmol/L, N (%) | 25 (66%) | 26 (67%) | .94 |
(1)Median (range).